QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.014464v1 35/6/859    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soars, M. G. Articles by Riley, R. J. Search for Related Content PubMed PubMed Citation Articles by Soars, M. G. Articles by Riley, R. J.

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Department of Physical and Metabolic Science, AstraZeneca Charnwood, Loughborough, Leics, England

The wealth of information that has emerged in recent years detailing the substrate specificity of hepatic transporters necessitates an investigation into their potential role in drug elimination. Therefore, an assay in which the loss of parent compound from the incubation medium into hepatocytes ("media loss" assay) was developed to assess the impact of hepatic uptake on unbound drug intrinsic clearance in vivo (CL_{int ub in vivo}). Studies using conventional hepatocyte incubations for a subset of 36 AstraZeneca new chemical entities (NCEs) resulted in a poor projection of CL_{int ub in vivo} (r² = 0.25, p = 0.002, average fold error = 57). This significant underestimation of CL_{int ub in vivo} suggested that metabolism was not the dominant clearance mechanism for the majority of compounds examined. However, CL_{int ub in vivo} was described well for this dataset using an initial compound "disappearance" CL_int obtained from media loss assays (r² = 0.72, p = 6.3 x 10^-11, average fold error = 3). Subsequent studies, using this method for the same 36 NCEs, suggested that the active uptake into human hepatocytes was generally slower (3-fold on average) than that observed with rat hepatocytes. The accurate prediction of human CL_{int ub in vivo} (within 4-fold) for the marketed drug transporter substrates montelukast, bosentan, atorvastatin, and pravastatin confirmed further the utility of this assay. This work has described a simple method, amenable for use within a drug discovery setting, for predicting the in vivo clearance of drugs with significant hepatic uptake.

This article has been cited by other articles:

				N. A. Hosea, W. T. Collard, S. Cole, T. S. Maurer, R. X. Fang, H. Jones, S. M. Kakar, Y. Nakai, B. J. Smith, R. Webster, et al. Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches J. Clin. Pharmacol., May 1, 2009; 49(5): 513 - 533. [Abstract] [Full Text] [PDF]

				T. Watanabe, H. Kusuhara, K. Maeda, Y. Shitara, and Y. Sugiyama Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 652 - 662. [Abstract] [Full Text] [PDF]

				K. Grime, P. J. H. Webborn, and R. J. Riley Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678. [Abstract] [Full Text] [PDF]

				S. W. Paine, A. J. Parker, P. Gardiner, P. J. H. Webborn, and R. J. Riley Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1365 - 1374. [Abstract] [Full Text] [PDF]